To further explore their function in mediating the enhanced anti-tumor immunity of ADAM17 deficient CD8+ T cells, we examined their expression in WT and ADAM17 deficient CD8+ TILs in the ACT tumor model (Fig. 3c). The gene discussed is ADAM17; the disease is neoplasm.